Oritavancin Demonstrates Superior In Vitro Activity To Vancomycin And Metronidazole Against C. Difficile Bacteria

Targanta Therapeutics Corporation released data from two studies comparing the in vitro activity of its lead antibiotic drug candidate, oritavancin, to that of other antibiotics against Clostridium difficile bacteria. Results are being presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in Chicago, IL. C. [click link for full article]

More: continued here

Filed under: GastroIntestinal / Gastroentorology on September 20th, 2007